SOUTH SAN FRANCISCO, Calif., March 18 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that it will provide a live webcast for its Investor Day on March 25, 2010 at 10:00am EDT. Members of Rigel's senior management team will provide an overview of the company's current product pipeline.
About Rigel (www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
CONTACT: Raul Rodriguez, +1-650-624-1302, invrel@rigel.com, or Ryan
Maynard, +1-650-624-1284, invrel@rigel.com, both of Rigel Pharmaceuticals,
Inc.
Web site: http://www.rigel.com/
